IBD: Incidence of adverse reactions to the treatment of IBD-combined prostate cancer by radiation therapy

BACKGROUND: Patients with inflammatory bowel disease (IBD) may develop complications associated with radiation therapy for prostate cancerHowever, the available data are limited, so this study is intended to study radiation therapy in patients with IBD with prostate cancermethod: This study is a retrospective cohort studyIncluded in IBD patients who diagnosed and treated prostate cancer between 1996 and 2015IbD, IBD-related hospitalizations and IBD-related surgical events, and 1, 2 and 5 years of survival were assessed during the 6, 12 and 24 months of cancer diagnosisThe recurrence of IBD is recorded by the therapist, so the treatment changes accordinglyresults: This study identified a total of 100 patients with IBD and prostate cancerForty-seven cases received external beam radiation or brachytherapy, and 53 received non-radiation therapyIn the 6 months after the cancer diagnosis (10.6% VS 5.7%) and 6-12 months (4.3% VS 1.9%), patients receiving radiation therapy had two times as many seizures of inflammatory bowel diseaseIn the multi-logical regression analysis, radiotherapy (OR:4.82; 95% confidence interval of 1.15-20.26) is an important predictor of recurrenceHowever, there was no significant difference in the rates of hospitalization or surgery associated with IBDconclusion: In this retrospective, multicenter study, patients receiving radiation therapy saw a twice-increased incidence of recurrence of the disease in the first year after the diagnosis of prostate cancer, but there was no difference in inpatient or surgery associated with IBD